Home › Bipolar Disorder › New York › Staten Island
Bipolar Disorder clinical trials in Staten Island, NY
3 studies for Bipolar Disorder are looking for participants at sites in and around Staten Island (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
RecruitingPhase 3
- Richmond Behavioral Associates, Staten Island
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
RecruitingPhase 3
- Richmond Behavioral Associates, Staten Island
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
RecruitingPhase 3
- Richmond Behavioral Associates, Staten Island
About Bipolar Disorder
Bipolar disorder is a mood disorder that can cause intense mood swings. It's also called manic depression. Learn about the types, symptoms, treatment, and more.
More about Bipolar Disorder on MedlinePlus
Bipolar Disorder trials in other cities
- Houston, TX10 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Little Rock, AR6 studies
- Atlanta, GA6 studies
- Hialeah, FL5 studies
- Miami, FL5 studies
- Austin, TX5 studies
- Cambridge, MA5 studies
- Orange, CA5 studies
- West Palm Beach, FL4 studies
- O'Fallon, MO4 studies
Other studies in Staten Island
- Breast Cancer40 studies
- Non-Small Cell Lung Cancer19 studies
- Prostate Cancer16 studies
- Acute Myeloid Leukemia14 studies
- Multiple Myeloma13 studies
- Lung Cancer12 studies
- Cancer (all types)11 studies
- Bladder Cancer11 studies
- Endometrial Cancer11 studies
- Metastatic Cancer10 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Ovarian Cancer9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.